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2818Objective: Small series of thoracotomy for mitral valve repair have demonstrated clinical benefit. This multi-
institutional administrative database analysis compares outcomes of thoracotomy and sternotomy approaches
for mitral repair.
Methods: The Premier database was queried from 2007 to 2011 for mitral repair hospitalizations. Premier con-
tains billing, cost, and coding data from more than 600 US hospitals, totaling 25 million discharges. Thoracot-
omy and sternotomy approaches were identified through expert rules; robotics were excluded. Propensity
matching on baseline characteristics was performed. Regression analysis of surgical approach on outcomes
and costs was modeled.
Results: Expert rule analysis positively identified thoracotomy in 847 and sternotomy in 566. Propensity match-
ing created 2 groups of 367. Mortalities were similar (thoracotomy 1.1% vs sternotomy 1.9%). Sepsis and other
infections were significantly lower with thoracotomy (1.1% vs 4.4%). After adjustment for hospital differences,
thoracotomy carried a 17.2% lower hospitalization cost ($8289) with a 2-day stay reduction. Readmission
rates were significantly lower with thoracotomy (26.2% vs 35.7% at 30 days and 31.6% vs 44.1% at
90 days). Thoracotomy was more common in southern and northeastern hospitals (63% vs 37% and 64% vs
36%, respectively), teaching hospitals (64% vs 36%) and larger hospitals (>600 beds, 78% vs 22%).
Conclusions: Relative to sternotomy, thoracotomy for mitral repairs provides similar mortality, less morbidity,
fewer infections, shorter stay, and significant cost savings during primary admission. The markedly lower read-
mission rates for thoracotomy will translate into additional institutional cost savings when a penalty on hospitals
begins under the Affordable Care Act’s Hospital Readmissions Reduction Program. (J Thorac Cardiovasc Surg
2014;148:2818-22)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surtranslating the successes of laparoscopic surgery into
the field of limited-access mitral surgery.1-4 Several
champions and institutional series have shown differential
benefits of this approach relative to sternotomy; these
benefits include reductions in cost, hospital stay, and
blood transfusions. with an overall faster recovery.5-13
Unfortunately, these studies have been limited by small
size or lack of financial and long-term outcomes. To provide
greater insight into the hospital costs associated with mini-
mally invasive mitral surgery, a group of experienced mini-
mally invasive cardiac surgeons (Economic Workgroup on
Valvular Surgery; Table E1) examined a cross-section of
United States hospital billing and coding data related to iso-
lated mitral valve repair (IsoMVRep). The purpose of this
study was to analyze the real-world clinical and economic
outcomes of thoracotomy compared with those of sternal
approaches for IsoMVRep.MATERIALS AND METHODS
Data Source
The Premier database is extensively used for economic analyses,
including those of cardiothoracic surgery.14-18 It contains, with patient
identifying data removed, complete patient billing, hospital cost, and
coding histories from more than 600 US health care facilities.19 This studygery c December 2014
Abbreviations and Acronyms
ICD-9 ¼ International Classification of
Diseases, Ninth Edition
IsoMVRep ¼ isolated mitral valve repair
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tional review board waiver of informed consent was obtained from the New
England Institutional Review Board, and an exemption was obtained
(NEIRB 13-203). Patients included those older than 18 years who under-
went IsoMVRep through either a thoracotomy or sternotomy incision be-
tween 2007 and 2011. IsoMVRep was identified for visits having the
primary International Classification of Diseases, Ninth Edition (ICD-9)
procedure code classification of 35.12. Patients who underwent coronary
artery bypass grafting in conjunction with IsoMVRep, underwent another
concomitant valve operation, or underwent procedures utilizing robotic
technology were excluded.
A set of expert rules were developed to text mine the charge master
billing files of the Premier database to identify surgical approach as either
thoracotomy or sternotomy (any type, including partial). Figure E1 dis-
plays these expert rules for procedure identification and attrition. For all
eligible patients, elements describing adverse events, hospital cost, surgery
time, hospital stay, and readmissions were obtained from the database. Cost
analysis reflected the actual cost of the procedure to the hospital. The pre-
operative All Patient Refined Diagnosis-Related Groups severity level was
used as an index of clinical comorbidity. The 3M All Patient Refined
Diagnosis-Related Groups Classification System, a widely adopted propri-
etary risk-adjustment classification tool, uses information from routine
claims data to produce valid and reliable severity measurement and risk-
adjustment scores.20 It is used to account for differences related to an indi-
vidual’s severity of illness or risk of mortality in large data sets. Comorbid
conditions that might influence procedure selection or outcomes of interest,
such as previous organ transplant, the presence of pulmonary disease, or
diabetes mellitus, were obtained through ICD-9 diagnosis and procedure
codes. Information on sociodemographic characteristics and health insur-
ance status was also included, as were descriptors of the care setting,
namely census region, urban or rural setting, teaching hospital status,
and facility bed count. Adverse events were identified by ICD-9 codes
and summed into categories (Table E2).
Statistical Analyses
The objective of this study was to use the Premier hospital database to
compare clinical and economic outcomes among patients undergoing Iso-
MVRep through a thoracotomy versus any sternal approach. Outcomes of
interest included adverse events, hospital costs, hospital stay, and readmis-
sion rates. Propensity scoring was used to create well-matched groups for
comparison. Extensive details of the statistical methodology are contained
in the Appendix E1.RESULTS
Data analysis identified 6007 patients undergoing
IsoMVRep. Expert rule analysis positively identified
IsoMVRep by thoracotomy in 847 cases and by sternotomy
in 566 cases. By means of propensity matching, 2 balanced
groups of 367 patients were created (Table 1). Frequencies
of comorbid conditions were equally distributed. Mortality
was not statistically different between the 2 groups (1.1%
for thoracotomy approach vs 1.9% for any sternotomy
approach). Important clinical outcomes are listed inThe Journal of Thoracic and CarTable 2. Neurologic (2.5% vs 2.2%), pulmonary (39.5%
vs 37.3%), and wound complications (4.9% vs 6.5%)
were not statistically different between the thoracotomy
and sternotomy groups, respectively. Sepsis and other infec-
tions were significantly lower with a thoracotomy approach
(1.1% vs 4.4%; P<.0065). A thoracotomy was more likely
than a sternotomy to be performed in southern and north-
eastern hospitals (63% vs 37% and 64% vs 36% res-
pectively; P< .0001), teaching hospitals (64% vs 36%;
P < .0001), and larger hospitals (>600 beds, 78% vs
22%; P<.0001; Table 3). Table 4 lists expenditures by sur-
gical approach, as broken into various cost centers. After
adjustment for hospital differences, patients treated through
a thoracotomy had a 17.2% lower average primary hospi-
talization cost ($8289). Themean stay with a thoracotomy
approach was 7.94 days, versus 10.2 days with any ster-
notomy approach. Significantly, 30- and 90-day readmis-
sion rates were lower in the thoracotomy group (26.2%
vs 35.7%; P< .0052; and 31.6% vs 44.1%; P< .0005,
respectively).
DISCUSSION
This study is a real-world analysis of IsoMVRep that draws
its data frommore than 600 diverse hospitals participating in
the Premier database. These institutions have contributed
their data, stripped of patient identifiers, for patient billing,
hospital cost, and coding histories into a communal database
to allow effective comparative cost analysis. With such
geographic and demographic variations, we were able to
note significant regional differences in greater use of thora-
cotomy for IsoMVRep in southern and northeastern, teach-
ing, and larger hospitals. Although one could argue that
larger hospitals and teaching hospitals have the necessary
critical mass to support lesser invasive cardiac surgery, it is
unknown why thoracotomies were performed in greater pro-
portion in southern and northeastern geographic areas.
The overall mortality reported here for mitral repair
(1.49%) is similar to that reported in the Society of
Thoracic Surgeons registry for the same period and rein-
forces the validity of this data set. As reported before, this
large propensity-matched series confirmed that IsoMVRep
through a thoracotomy carried comparable mortality and
significantly decreased rates of sepsis and infection, hospi-
tal cost, and length of stay relative to sternotomy. These
differences are in contrast to an earlier report by Suri and
colleagues,21 which propensity matched and compared ster-
notomy versus port-access approaches for mitral repair.
Although Suri and colleagues21 did demonstrate significant
decreases in postoperative ventilatory support with port-
access procedures, there were no other differences in
outcomes. It is unclear whether this difference was due to
its comparison of 2 university series, as opposed to real-
world data, or whether there was more discriminatory
power in our multi-institutional analysis.diovascular Surgery c Volume 148, Number 6 2819
TABLE 3. Hospital characteristics after matching
Category
Thoracotomy Sternotomy
P value
By
visits
By
hospital
By
visits
By
hospital
N % N % N % N %
Total 367 100 39 100 367 100 52 100
Census region
Northeast 80 21.8 11 28.2 51 13.9 7 13.5 <.0001
Midwest 17 4.6 7 18.0 29 7.9 7 13.5
South 249 67.9 12 30.8 146 39.8 24 46.2
West 21 5.7 9 23.1 141 38.4 14 26.9
Location
Urban 363 98.9 37 94.9 350 95.4 46 88.5 .0040
Not urban 4 1.1 2 5.1 17 4.6 6 11.5
Type
Teaching 325 88.6 21 53.9 185 50.4 24 46.2 <.0001
Nonteaching 42 11.4 18 46.2 182 49.6 28 53.9
Bed count
<200 3 0.8 2 5.1 6 1.6 1 1.9 <.0001
200-400 22 6.0 13 33.3 122 33.2 22 42.3
401-600 75 20.4 11 28.2 163 44.4 17 32.7
>600 267 72.8 13 33.3 76 20.7 12 23.1
TABLE 1. Demographic characteristics after matching of patients
undergoing mitral repair
Category
Thoracotomy Sternotomy
P valueN % N %
Total 367 100 367 100
Age (y) .7155
<30-60 138 37.6 146 39.8
60-69 106 28.9 97 26.4
70 123 33.5 124 33.8
Race or ethnicity .2049
White 279 76.0 263 71.7
African American 24 6.5 37 10.1
Hispanic 4 1.1 8 2.2
Other 60 16.4 59 16.1
Sex >.9999
Female 161 43.9 161 43.9
Male 206 56.1 206 56.1
Insurance >.9999
Commercial 12 3.3 12 3.3
Medicare 179 48.8 179 48.8
Medicaid 12 3.3 12 3.3
Managed care 147 40.1 147 40.1
Other 17 4.6 17 4.6
Health status .4919
APR-DRG severity
level 1 or 2
141 38.4 132 36.0
APR-DRG severity
level 3 or 4
226 61.6 235 64.0
APR-DRG, All Patient Refined Diagnosis-Related Groups.
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significant savings with the thoracotomy approach, with a
reduction in the average primary hospitalization cost ofTABLE 2. Adverse events of propensity-matched groups after mitral
repair
Category
Thoracotomy Sternotomy
P valueN % N %
Total 367 100 367 100
Neurologic complications* 9 2.5 8 2.2 .8062
Total pulmonary complications
(infections plus
noninfections)y
145 39.5 137 37.3 .5438
Pulmonary complications
excluding infections
126 34.3 105 28.6 .0951
Total infectionsz 23 6.3 43 11.7 .0099
Pulmonary infectionsx 19 5.2 32 8.7 .0591
Sepsis and other infectionsk 4 1.1 16 4.4 .0065
Wound complications{ 18 4.9 24 6.5 .3403
In-hospital deaths 4 1.1 7 1.9 .3621
*Ischemic stroke, hemorrhagic stroke, transient cerebral ischemic attack. yAcute
respiratory failure, pulmonary insufficiency, atelectasis or pulmonary collapse, pneu-
monia. zPneumonia, sepsis, bacteremia or systemic inflammatory response syn-
drome, postoperative infection. xPneumonia. kSepsis, bacteremia or systemic
inflammatory response syndrome, postoperative infection. {Hematoma, seroma, or
hemorrhage complicating a procedure; wound disruption or dehiscence.
2820 The Journal of Thoracic and Cardiovascular Sur$8289 (17.2%). Part of this savings is attributable to a
2-day reduction in hospital stay associated with a thoracot-
omy approach. In addition, as previously reported,10,22
blood use (as inferred from mean cost of $1122 for
thoracotomy vs $1671 for sternotomy) was significantly
reduced with a thoracotomy approach.
Although roboticmitral repairs were specifically excluded
from this study, parallels between recent robotic economic
studies and ours can be noted. Suri and associates23 recently
reviewed the Mayo Clinic experience and concluded that
robotics alongwith process improvement can be cost neutral,
increasing ‘‘the affordability of new technologies capable of
improving early patient outcomes.’’ Likewise, Mihaljevic
and colleagues24 performed propensity-based analyses of
the economic cost of robotics for degenerativemitral repairs.
They noted that after a threshold of 50 to 100 cases a year the
cost of robotically assisted operations overlapped those of
conventional approaches. As such, in exchange for higher
procedural costs, robotic valve repair offered the clinical
benefit of the least invasive surgery, the lowest postoperative
cost, and the fastest return to work.
An important and interesting discovery in this analysis
was the decreased readmission rates associated with the
thoracotomy approach. At both 30 and 90 days, the thora-
cotomy cohort had significantly lower readmission rates.
Although this difference was not calculated into the hos-
pital cost saving presented here, it will certainly translate
into further institutional cost savings as the Patient Pro-
tection and Affordable Care Act (Obama Care) penalty
on hospitals begins under the Act’s Hospital Readmis-
sions Reduction Program.25gery c December 2014
TABLE 4. Health care use and costs after matching
Thoracotomy Sternotomy
Total hospital costs
Median $31,515 $37,495
Mean $37,156 $47,683
SD $19,624 $35,865
Hospital costs by cost center
Blood bank
Median $507 $799
Mean $1122 $1671
SD $2241 $2436
Operating room
Median $8886 $8029
Mean $9602 $8929
SD $4679 $5685
Other
Median $523 $246
Mean $3566 $1162
SD $4833 $3156
Pharmacy
Median $2078 $2232
Mean $2823 $4876
SD $2947 $15,211
Radiology
Median $438 $460
Mean $673 $807
SD $699 $1125
Respiratory
Median $688 $949
Mean $1226 $1664
SD $1788 $2417
Room and board
Median $5622 $9075
Mean $7372 $13,655
SD $9090 $17,226
Intensive care unit
Median $2662 $4177
Mean $4311 $8091
SD $7257 $15,073
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This study had some important limitations. This analysis
was limited to a 90-day perioperative period, which limits
any analyses related to potential long-term complications.
Although thoracotomy approaches and partial sternotomy
approaches are considered minimally invasive, data limita-
tions did not allow for a distinction between and full and
partial sternotomy approaches in this study. This large
multi-institutional comparison of the sternal versus non-
sternal approach for IsoMVRep, however, at the minimum
shows the benefits of thoracotomy versus any sternal
approach. These differences would be even greater if partial
sternotomies were not included in the control group.26 In
addition, although the total hospital costs are accurate,
different institutions may have placed various items intoThe Journal of Thoracic and Cardifferent cost centers, and these differences may limit the
usefulness of individual cost center analyses.
Finally, the arterial perfusion approach (antegrade or
retrograde) was not available to analyze in this data set.
The senior author (E.A.G.) has previously reported on
both the changing incidence of arterial perfusion strategies
and their differential outcomes.27 This study was designed
to accurately test differences of surgical incision, however,
not perfusion strategies. As such, our algorithm included the
possibility of either femoral perfusion or central aortic
perfusion.CONCLUSIONS
Relative to sternal approaches, a thoracotomy approach for
IsoMVRepprovides similarmortality and lessmorbiditywith
fewer infections, shorter hospital stay, and significant cost
savings during the primary admission. From an economic
perspective, the markedly lower readmission rates associated
with thoracotomy will translate into additional institutional
cost savings when the Patient Protection and Affordable
Care Act (Obama Care) penalty on hospitals begins with
the Act’s Hospital Readmissions Reduction Program.References
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APPENDIXE1.DETAILED STATISTICAL STRATEGY
AND METHODOLOGY
From more than 25 million inpatient admissions in the
Premier database, 6007 IsoMVRep procedures were identi-
fied. Next, the type of arterial cannulation (aortic, femoral,
both, or unspecified) was determined. Of those patients who
had femoral arterial cannulation or both femoral and aortic
cannulation, we looked at whether a bone saw blade or
bone wax was ever used as a determinant of sternotomy
approach. These 847 patients—with femoral or combined
arterial cannulation, no bone saw use, and no bone wax
use—comprised the thoracotomy cohort.
A quasi-randomization method, called propensity sco-
ring, was used to create groups of analyzable patients who
were well matched. Propensity scores were assigned on
the basis of likely predictors of the outcome of interest.
Covariates on which to match were selected on the basis
of their availability in the Premier database as well as their
general acceptance as factors associated with the outcomes
of interest.
The goal of this propensity-matching analysis was to find
pairs of patients undergoing and not undergoing a thoracot-
omy for IsoMVRep who shared similar propensities for
candidacy for the procedure on the basis of the matching
variables. In addition, this analysis sought to maximize
the number of matched patients while ensuring that cohorts
were not significantly different with respect to relevant
characteristics.
A statistical software (SAS Institute Inc, Cary, NC)
macro from the Mayo Clinic was used; this macro used
‘‘nearest neighbor matching’’ on the estimated propensity
scores to choose matches for the patients who underwent
a thoracotomy procedure.26 Propensity scores were calcu-
lated for likelihood of thoracotomy procedures for each of
the patients included in the analysis on the basis of a non-
parsimonious multivariable logistic regression model.
Patients undergoing a thoracotomy for IsoMVRep were
then matched with patients undergoing any sternotomy
for IsoMVRep with a 1:1 ratio exactly (caliper¼ 0) on their
sex. They were simultaneously matched within5 years on
age and within a value of 0.0001 on their propensity for
undergoing a sternotomy for IsoMVRep. Patient character-
istics (race or ethnicity, marital status, region, and insur-
ance) and co-morbid conditions (severity index, angina,
dysrhythmias, chronic obstructive pulmonary disease, dep-
ression, extensive aortic atherosclerosis, kidney disease,
previous coronary angioplasty, myocardial infarction [acute
or old], and other coronary artery disease) were adjusted in
the propensity score model.
Once the matched pairs had been obtained, to assess the
extent to which the propensity matching reduced con-
founders, the distribution of several variables before and
after matching were compared among the patients in the
cohorts, including age, sex, race or ethnicity, insurance
type, health status, region, and comorbid conditions. Group
comparisons were made with c2 tests.
Because hospital costs have been found to be positively
skewed, a generalized linear model with a gamma distribu-
tion and a log link function was used to adjust for differ-
ences in hospital characteristics (teaching vs nonteaching,
urban vs rural, and bed count) and to calculate the corre-
sponding least square means of overall cost for the hospital
stay within each matched cohort. Adverse events (defined
by ICD-9 coding in Table 2) were summarized in tables
by cohort, with P values for the differences in event rates
calculated for each event category (neurologic, pulmonary,
infection, and wound). Analyses were performed with SAS
software (version 9.2).
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FIGURE E1. Flowchart demonstrating the expert rules used for procedure identification and attrition.
TABLE E1. Economic Workgroup on Valvular Surgery
Physician Hospital or group practice Location
Gorav Ailawadi, MD University of Virginia Charlottesville, Va
Mark Anderson, MD Einstein Medical Center Philadelphia, Pa
Glenn Barnhart, MD Swedish Medical Center Seattle, Wash
Scott Goldman, MD Main Line Cardiothoracic Surgery Wynnewood, Pa
Eugene Grossi, MD NYU Langone Medical Center New York, NY
Clifton Lewis, MD Princeton Baptist Medical Center Birmingham, Ala
Michael Mack, MD The Heart Hospital Baylor Plano Dallas, Tex
Chris Malaisrie, MD Northwestern Memorial Hospital Chicago, Ill
John Mehall, MD Penrose-St. Francis Health Services Colorado Springs, Colo
Robert Riley, MD Arizona Cardiovascular Scottsdale, Ariz
Evelio Rodriguez, MD Saint Thomas Heart Nashville, Tenn
Eric Roselli, MD Cleveland Clinic Cleveland, Ohio
William Ryan, MD The Heart Hospital Baylor Plano Dallas, Tex
Arash Salemi, MD New York Presbyterian-Weill Cornell Medical Center New York, NY
J. Michael Smith, MD TriHealth Heart Institute Cincinnati, Ohio
J. Alan Wolfe, MD Northeast Georgia Physicians Group Atlanta, Ga
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TABLE E2. Adverse events (International Classification of Diseases, Ninth Edition codes)
Adverse events by category ICD-9 codes
Neurologic complications
Ischemic stroke 433.x1, 434.x1, 997.02
Hemorrhagic stroke 430, 431, 432.x
Transient cerebral ischemic attack 435.x
Pulmonary complications—infections
Pneumonia 480.x, 481, 482.x-484.x, 485, 486, 487, 490, 491.21, 491.22, 507.0,
510.0, 510.9, 513, 513.0, 513.1, 519.01, 997.31, 997.32
Pulmonary complications—noninfectious
Acute respiratory failure and pulmonary insufficiency 518.81, 518.84, 518.5
Atelectasis or pulmonary collapse 518.0
Pulmonary complications—excluding infections
Lung complications noninfectious 511.0-511.1, 511.89, 511.9, 512.0, 512.1, 514, 518.4, and 997.39
(if patient not already in another pulmonary category)
Sepsis and other infections
Septicemia, bacteremia, or SIRS 038.xx, 790.7, 995.9x
Postoperative infection 998.5x, 999.0, 999.3x
Wound complications
Hematoma, seroma, or hemorrhage complicating a procedure 998.1x
Wound disruption or dehiscence 998.3x
Death
In-hospital death From Premier data
ICD-9, International Classification of Diseases, Ninth Edition; SIRS, systemic inflammatory response syndrome.
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